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Abstract: G enomic instability, including genetic muta-
tions and chromosomal rearrangements, can lead to 
cancer development. Aberrant DNA methylation occurs 
commonly in cancer cells. The aim of this study is to 
determine the effects of a specific chromosomal lesion, 
the BCR-ABL translocation t(9:22), in establishing DNA 
methylation profiles in cancer. Materials and methods We 
compared DNA methylation of 1,505 selected promoter 
CpGs in chronic myelogenous leukemia (CML), acute 
lymphoblastic leukemia (ALL) with and without the Phil-
adelphia chromosome t(9:22), CD34+ hematopoietic stem 
cells transfected with BCR-ABL, and other tumors without 
BCR-ABL (acute promyelocytic leukemia (APL) and gastro-
intestinal stromal tumors (GIST). In this study, the DNA 
methylation profile of CML was more closely related to 
APL, another myeloid leukemia, than Ph+ ALL. Although 
DNA methylation profiles were consistent within a specific 
tumor type, overall DNA methylation profiles were not 
influenced by BCR-ABL gene translocation in the cancers 
and tissues studied. We conclude that DNA methylation 
profiles may reflect the cell of origin in cancers rather than 
the chromosomal lesions involved in leukemogenesis.
Keywords: DNA methylation; Chronic Myelogenous Leu-
kemia; Philadelphia Chromosome; Acute Promyelocytic 
Leukemia; Acute Lymphoblastic Leukemia; Gastrointesti-
nal Stromal Tumor; 5-azacytidine
1  Introduction
The genesis of cancer in any patient can trace its origin 
to a single cell that has acquired multiple genetic and 
epigenetic alterations. It may lead to the abnormal gene 
expression and protein function responsible for the varied 
malignant biological phenotypes. Genetic mutations such 
as point mutations, chromosomal deletions, gene dupli-
cation and chromosomal translocations can lead to acti-
vation of oncogene or inactivation tumor suppressor gene 
[1]. Epigenetic alterations in DNA methylation, histone tail 
modifications and miRNA are also known to be associated 
with changes in gene expression level [2,3]. Aberrant DNA 
methylation at CpG islands located in promoter regions 
is a well-known phenomenon in cancer, and this DNA 
hypermethylation is associated with aberrant silencing of 
tumor suppresser genes [2]. The current dogma of cancer 
epigenetics states that aberrant DNA methylation leads to 
gene silencing, and this is supported by evidence of DNA 
methyltransferase inhibitors being reactivated in cancer 
through hypomethylation [4,5].
Here, we examined DNA methylation in chronic mye-
logenous leukemia (CML) and other cancers in order to 
better understand the etiology of aberrant DNA methyla-
tion in cancer. CML is a homogenous cancer in that the 
BCR-ABL oncogene is the sole chromosomal lesion that 
leads to the development of the disease phenotype in 
all cases. Previous studies have transfected the BCR-ABL 
fusion gene in cells or transgenic mice to confirm the 
dependence of this leukemia on this genetic event [6-8]. 
It is a clonal disease that originates from a single trans-
formed hematopoietic stem cell or multipotent progeni-
tor cell, where the Philadelphia translocation t(9:22) first 
occurred and is shared by all cancer cells [9,10]. Because 
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of this shared chromosomal lesion, this cancer has a very 
homogenous clinical course and response to imatinib 
mesylate (Gleevec®). Imatinib mesylate is also used to 
treat gastrointestinal stromal tumors (GISTs) by inhibiting 
tyrosine kinase activity. Approximately 95% of GISTs stain 
positively for the CD117 antigen by immunohistochemis-
try and 80~85% of GISTs exhibit activating KIT mutations 
that are another target for imatinib mesylate therapy 
[11,12]. Epigenetic modifications, particularly increased 
gene promoter DNA methylation, have been shown to be 
associated with imatinib mesylate resistance [13-15]. To 
the best of our knowledge, the mechanism behind the 
association between gene promoter DNA methylation and 
response to imatinib mesylate treatment is not known. 
However, one possible mechanism might be an aberrant 
expression of genes related to the transport of imatinib 
mesylate to leukemic cells.  
Acute promyelocytic leukemia (APL) is similar to CML 
in that it is a leukemia characterized by a specific genetic 
event. The translocation t(15:17) generates the oncogenic 
fusion protein PML-RARa that is responsible for 99% of 
APL cases, which has distinct clinical features compared 
to CML [16]. Chromosomal abnormalities have been fre-
quently described in acute lymphoblastic leukemia (ALL), 
and the most common is the Philadelphia chromosome 
(Ph). The BCR-ABL translocation is found in approxi-
mately 20~30% of adults and in 5% of pediatric cases 
of ALL, respectively [17,18]. It should be noted that two 
common translocation sites have been described for the 
BCR-ABL fusion gene in CML and Ph+ ALL. One transloca-
tion creates a p210 fusion protein that is found in 95% of 
CML and one-third of ALL, whereas a slightly smaller p190 
is found in less than 5% of CML patients, and two-thirds of 
adults and more than 90% of children with Ph+ ALL [19]. 
However, the two forms of BCR-ABL are not exclusive for 
one disease or the other, and in fact, are interchangeable 
without significant changes in disease phenotype.
Genomic mutations are associated with a high fre-
quency of cancer-specific hypermethylation of particular 
loci, and these may be associated with distinct DNA meth-
ylation subgroups [20-23]. Aberrant DNA methylation has 
been investigated in several types of leukemia for further 
insight into cytogenetic subtypes [24-28]. However, there 
have been no studies into whether genomic transloca-
tions might be responsible for aberrant DNA methylation 
across the genome. Here, in order to examine the etiology 
and role of DNA methylation in cancer, DNA methylation 
profiling of CML was compared to APL and ALL, which 
have a unique genomic translocation. We also compared 
DNA methylation patterns between CML and GIST which 
are treated with the same drug, imatinib mesylate. The 
role of the BCR-ABL translocation in DNA methylation 
was studied in more detail by examining DNA methyl-
ation profiles of Ph+ ALL and hematopoietic stem cells 
transfected with BCR-ABL (hereafter called Ph+ CD34+) 
[6]. We also examined DNA methylation changes that 
are involved in the biology of the ordered progression of 
CML from chronic phase to accelerated phase and finally 
blast phase. The effect of DNA methyltransferase inhibi-
tors on DNA methylation in cancer was examined through 
the serial profiling of DNA methylation of a CML patient 
treated with the DNA methyltransferase inhibitor azaciti-
dine.
2  Materials and methods
2.1  Patient information
Samples of patients with chronic myelogenous leukemia 
(CML), acute promyelocytic leukemia (APL), gastrointes-
tinal stromal tumor (GIST) and acute lymphoblastic leu-
kemia (ALL) were obtained from established tissue banks 
at University of Southern California and M. D. Anderson 
Cancer Center. All samples were collected according to the 
institutional review board of the University of Southern 
California and M. D. Anderson Cancer Center in accord-
ance with institutional guidelines. A brief description of 
the study samples, such as gender, age, and specimen 
type, is provided in Supplementary Data 1. Treatment 
with the DNA methyltransferase inhibitor, 5-azacytidine, 
has been described previously [29]. CD34+ hematopoietic 
stem cells isolated from umbilical cords and transfected 
with the BCR-ABL gene (Ph+ CD34+) were generously pro-
vided by Dr. Ravi Bhatia [6]. Briefly, the controls expressed 
green fluorescent protein (GFP) alone, and the cell frac-
tions were collected according to low or high BCR-ABL 
expression. The cells were cultured for 7 or 14 days before 
harvest to examine DNA methylation. 
2.2  Genomic DNA extraction and DNA meth-
ylation analysis 
DNA was extracted using phenol-chloroform and stored at 
-80°C until required.  DNA extracted from the samples was 
modified with sodium bisulfite using the 96 Zymo EZ DNA 
Methylation kit (Zymo Research, Orange, CA, USA). DNA 
methylation status was assessed using the GoldenGate 
Assay for Methylation Cancer Panel I from Illumina (La 
Jolla, CA, USA) and performed at the University of South-
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ern California Epigenome Center, as described elsewhere 
[30]. The commercially available DNA Methylation Cancer 
Panel I interrogates 1,505 independent CpG sites. Data 
were reported as beta values, with the methylation status 
of the interrogated CpG site calculated as the ratio of the 
fluorescent signal from methylated allele relative to the 
sum of both methylated and unmethylated alleles. β values 
with detection p-values > 0.01 were removed from further 
analysis. The raw DNA methylation data will be available 
upon request. We used genomic DNA prepared following 
whole-genome amplification (WGA) as an ‘unmethylated’ 
control, and MSssI-treated DNA as a fully ‘methylated’ 
control. WGA kits (REPLI-g, Qiagen, Doncaster, Australia) 
were used to amplify DNA from normal blood as recom-
mended, and these were bisulfite-treated as described 
above. The methylation reactions were carried out in 1x 
M.SssI buffer with 160μM S-adenosyl methionine (SAM) 
(supplied with M.SssI by New England Biolabs, Ipswich, 
MA, USA), and DNA was treated three times with M.SssI 
prior to bisulfite treatment. 
2.3  Bisulfite-PCR pyrosequencing 
measurements
Bisulfite-PCR pyrosequencing was performed for LINE-1 
assay [26]. We used the PyroGold Reagent kit (Biotage, 
Uppsala, Sweden) on a Pyrosequencing 96HS as previ-
ously described [31]. In brief, 10 µL PCR products for each 
sequencing reaction were immobilized onto streptavi-
din-coated beads (Streptavidin Sepharose HP, GE Health-
care Biosciences, Pittsburgh, PA, USA) in binding buffer 
(10 mM Tris-HCl, pH 7.6, 2 M NaCl, 1 mM EDTA, 0.1% 
Tween 20) for 10 min. The biotinylated template was puri-
fied with the Pyrosequencing vacuum prep tool (Biotage, 
Uppsala, Sweden) and incubated with 10pmol/reaction 
individually with each sequencing primer in annealing 
buffer (20 mM Tris-acetate, pH 7.6 and 2 mM MgAc2). 
The DNA strands were denatured at 80°C for 2 min and 
reannealed at room temperature for 10 min.  Sequenc-
ing was performed according to manufacturer’s instruc-
tions. The allele frequency (% cytosine or % thymidine) 
was calculated from the peak height, analyzed with the 
allele quantification module in the PSQ 96 HS software 
(Biotage, Uppsala, Sweden). Percentage of methylation 
was determined by the percentage of cytosine-to-thymi-
dine conversion (methylation= % cytosine/(% cytosine + 
% thymidine)).
2.4  Data analysis
Data from the Illumina GoldenGate Methylation microar-
rays were analyzed using the open-source programs 
Cluster 3.0 and Java Treeview. Cluster 3.0 was used to 
perform an unsupervised hierarchical cluster analysis 
by applying complete linkage clustering with a Euclid-
ean distance metric. The basic statistic and scatter plots 
were done using JMP, Version 7 (SAS Institute Inc., Cary, 
NC, USA). X-chromosome linked loci, loci that possibly 
contain single nucleotide polymorphisms (SNPs) and/
or repetitive elements were eliminated to increase the 
strength of analysis [31].
3  Results
3.1  DNA methylation analysis of CML, APL 
and GIST
We examined DNA methylation using the Illumina Gold-
enGate Methylation Assay, which simultaneously ana-
lyzes methylation at 1,505 CpG sites in 807 genes, in 36 
patients with CML, 18 patients with APL, five patients 
with GIST and six healthy controls. We analyzed 972 of 
these loci, as 533 loci are located on the X-chromosome or 
have previously been described to contain SNPs or repeat 
sequences that affect the DNA methylation analysis [31]. 
An unsupervised two-dimensional cluster analysis of 
these homogenous cancers demonstrated clear clustering 
by disease type, consistent with the theory that aberrant 
DNA methylation is not random but highly consistent 
within a specific cancer type, and that the DNA methyl-
ation profile is unique within a specific cancer (Figure 1). 
We found a high degree of correlation between DNA meth-
ylation profiles within each cancer (Pearson’s correlation 
CML= 0.927, APL= 0.915, and GIST= 0.892), and the corre-
lation between cancers was lower (Pearson’s correlation= 
0.852).
Unique DNA methylation profiles existed for CML, 
APL, and GIST by visual inspection (Figure 1, red arrows). 
The leukemia-specific methylated loci and the potential 
function of genes differentially methylated in leukemia 
were also analyzed by Ingenuity pathway analysis and 
listed in Supplementary Data 2. The DNA methylation pro-
files in these tumors enabled clustering by disease type, 
and the DNA methylation profiles were shared by individ-
uals with the same disease. Therefore, DNA methylation 
profiles were similar between specific cancers, but differ-
ent between CML, APL and GIST cancers. 
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3.2  The Philadelphia Chromosome and DNA 
methylation in leukemia
In order to understand the DNA methylation changes 
driven by t(9,22) in CML, we examined the DNA methyla-
tion profiles of CML and Ph+ ALL, a lymphoid malignancy 
which is also characterized by t(9:22). In addition, we 
examined CD34+ hematopoietic stem cells isolated from 
umbilical cords and transfected with the BCR-ABL gene 
(Ph+ CD34+)[6]. Two-dimensional unsupervised cluster 
analysis was performed using DNA methylation data from 
CML, ALL (Ph+ and Ph-), and CD34+ (Ph- and Ph+) (Figure 2) 
[6]. Here again, we found clear clustering by disease and 
cell type, but not by the presence or absence of BCR-ABL. 
Partial discrimination between CML and Ph+ ALL was 
possible despite the shared BCR-ABL genomic translo-
cation, and CML did not cluster with Ph+ CD34+. Ph+ ALL 
and Ph- ALL showed a distinct pattern of DNA methylation 
independently of the presence of the Philadelphia chro-
mosome. 
Next, a consensus DNA methylation profile for each 
disease was determined by calculating the mean DNA 
methylation beta value at each locus. The hierarchical 
clustering tree of mean methylation of all samples also 
supported the notion that the myeloid malignancy, CML 
(three phases based on clinical characteristics; chronic 
phase, accelerated phase, and blast crisis phase), is more 
closely related to the other myeloid malignancy, APL, 
than Ph+ CD34+ cells or Ph+ ALL (Figure 3). The difference 
in correlation was subtle, nonetheless consistent with the 
cluster analysis, and the highest correlation shown with 
CML was APL (r=0.9475), and not Ph+ CD34+ hematopoietic 
stem cells (r=0.9343) or Ph+ ALL (r=0.9416). Interestingly, 
there was a highly consistent DNA methylation profile 
between Ph+ and Ph- ALL, and between Ph+ CD34+ and Ph- 
CD34+ cells, despite differences in Philadelphia chromo-
some status (r=0.9621, p=2.2x10-16 and r=0.9633, p=1x10-10, 
respectively) (Figure 4).
Figure 1: DNA methylation analysis of homogenous cancers. Two-
dimensional unsupervised cluster analysis of DNA methylation in 36 
CML, 18 APL and five GIST patients, and six samples of peripheral 
blood from healthy controls. DNA methylation at 972 CpG sites are 
shown, with probes corresponding to sites on the X-chromosome 
and those known to contain SNPs were sequestered and not used 
for downstream analysis. Red arrows indicate clusters of DNA 
methylation that are specific for each disease. Blue represents low 
levels of DNA methylation (beta value close to 0) and yellow repre-
sents high level of DNA methylation (beta value close to 1).
Figure 2: DNA methylation profiles of Ph+ leukemias. Two-dimensio-
nal unsupervised cluster analysis of DNA methylation profiles asso-
ciated with the Philadelphia chromosome (CML, Ph+ CD34+, and Ph+ 
ALL) and counterparts (Ph- CD34+ and Ph- ALL). Blue represents low 
DNA methylation (beta value close to 0), and yellow represents high 
DNA methylation levels (beta value close to 1). Different leukemia 
types are represented by different color bars on the top of heatmap.
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3.3  DNA methylation changes with CML 
progression
The clinical course of untreated CML typically follows an 
ordered progression for almost all patients from an early 
chronic phase (CP) through an accelerated phase (AP) to 
terminal blast crisis phase (BP). The consistency of this 
progression among patients likely reflects the homo-
geneity of the disease, and also enabled us to examine 
DNA methylation changes involved in the progression of 
CML. Thus, we determined the DNA methylation changes 
found in different phases of CML. Subset analysis of our 
CML samples by chronic phase (n=23), accelerated phase 
(n=5), and blast phase (n=8) revealed 84 loci that clearly 
showed increased DNA methylation (mean β >0.01 and p 
value < 0.05) and 66 loci that showed a decrease in DNA 
methylation (β <0.01 and p value < 0.05) with CML progres-
sion (Figure 5A). The list of genes and Ingenuity pathway 
analysis are listed in Supplementary Data 3. Interestingly, 
we had a single patient for whom we had a series of blood 
samples taken at the time of diagnosis (chronic phase) 
and from the accelerated and blast phases. As a further 
validation of these identified loci, we plotted DNA meth-
ylation levels at 20 hyper- and hypomethylated loci in an 
independent set of serial samples from this single patient 
at the chronic, accelerated and blast phases (Figure 5B). 
DNA methylation changes of hypermethylation or hypo-
methylation with CML progression from 36 individual 
CML patients were well validated in the serial samples 
from a single patient.
3.4  The effect of azacitidine (5-azacytidine, 
Vidaza®) treatment upon DNA methylation 
changes in CML patient
We next wanted to determine the plasticity of the dis-
ease-specific DNA methylation changes in CML and 
changes involved in CML progression. We studied serial 
DNA methylation changes in a CML patient who became 
resistant to imatinib mesylate and developed blast crisis. 
The patient was then treated in a clinical trial with the 
DNA methyltransferase inhibitor, azacitidine (5-azacy-
tidine, Vidaza®) for three courses and responded with 
hematological improvement of white blood cell count 
(Clinical trial reported previously by Bernstein et al. [29] 
Patient #2, Table 1). Eventually, a more potent tyrosine 
kinase inhibitor, dasatinib (Sprycel®), became available 
and the patient’s therapy was switched. Serial periph-
eral blood samples were collected and the genome-wide 
changes in DNA methylation profile were studied by 
Illumina GoldenGate Methylation Assay and by bisulfite 
PCR-pyrosequencing to assess the LINE-1 DNA repetitive 
element in samples from the chronic phase, blast phase, 
azacitidine treatment and dasatinib treatment.
The patient was a 33-year-old female who was origi-
nally diagnosed with CML in 1999. The patient was treated 
with hydrea and then interferon, and finally imatinib 
mesylate in 2001, when it became available. The patient’s 
best response to therapy was only a partial cytogenetic 
response with 31% of cells being Ph+ by fluorescence 
in situ hybridization (FISH) after 18 months of therapy 
(March of 2003). The patient presented with a markedly 
elevated white blood cell (WBC) count of 306,000 cells/
mm3 and was found to be in myeloid blast crisis. The 
patient was started on the DNA methyltransferase inhib-
itor, azacitidine as part of a clinical trial at a dose of 25 
mg/m2 intravenously for five consecutive days in Course 
1 (28 day courses), 75 mg/m2 intravenously for Course 2, 
and 75 mg/m2 subcutaneously for Course 3 [29]. There was 
a dramatic decrease in the patient’s WBC count to normal 
by Course 2 of therapy (342,800 cells/mm3 to 5,200 cells/
mm3) (Figure 6A). This corresponded with a subtle but sig-
nificant decrease in global DNA methylation, as assessed 
by measuring DNA methylation of the LINE-1 repetitive 
element by pyrosequencing (Pearson’s correlation 0.67, p 
value=0.049), and a decrease in the average DNA methyl-
ation of 1,006 loci as measured by Illumina GoldenGate 
Figure 3: The hierarchical tree of leukemias with mean DNA methyla-
tion. Relationship of DNA methylation profile by clustering based 
analysis with different leukemias, GIST, Ph+/- CD34+ hematopoietic 
stem cells, and healthy controls. A close relationship is demonstra-
ted for the different phases of CML and myeloid leukemias (CML and 
APL), lymphoid leukemias (Ph+ ALL and Ph- ALL) and hematopoietic 
stem cells (Ph+/- CD34+). Relationships identified by clustering are 
independent of BCR-ABL status.
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Methylation Assay (including the original 972 loci ana-
lyzed in this study and those loci located on the X-chromo-
some loci). The maximum decrease in LINE-1 DNA meth-
ylation was 2.5% after treatment with azacitidine. It took 
three courses of treatment to reach this point, and this 
was consistent with the average gene-specific change at 
the 1,006 loci, which showed a mean beta value decrease 
of 0.03 after three courses of treatment (Figure 6B). 
According to visual inspection, changes in DNA methyla-
tion (the average of promoter gene methylation and global 
DNA methylation) occurred prior to changes in WBC levels 
(azacitidine Course 1 Day1, Course 2 Day 3, and off trial). 
The mean DNA methylation value of the CML progression 
loci (hypo- or hyper-) also responded to the DNA methyl-
transferase inhibitor drug (Figure 6C). The loci that were 
shown to be increasingly methylated during CML progres-
sion became less methylated during azacitidine treatment 
(mean beta value 0.61 to 0.48), and those loci at which 
methylation decreases during CML progression became 
increasingly methylated with azacitidine treatment (mean 
beta value 0.14 to 0.42) (Figure 6C).
4  Discussion
A unique aspect of our study was the ability to compare 
the DNA methylation profiles 1) between Ph+ leukemias 
and Ph- leukemias, 2) leukemias containing other chromo-
somal translocations (t(15,17), and 3) other solid tumors 
(GIST). Therefore, we were able to assess whether specific 
chromosomal lesions lead to the unique DNA methyla-
tion changes observed, or if the chromosomal lesions are 
independent of the observed DNA methylation profiles. 
We determined the aberrant DNA methylation profile 
involved in CML and its progression, and compared this 
profile to other cancers. We found that the DNA methyla-
tion profiles in CML were more closely related to those of 
another myeloid leukemia, APL, than other cancers that 
have the same chromosomal lesion, t(9:22). In addition, 
the DNA methylation profiles within ALL were similar and 
independent of the presence of the t(9:22). Finally, trans-
fection of the BCR-ABL gene into hematopoietic stem cells 
inducing a CML-like phenotype did not show a CML-like 
DNA methylation profile. Thus, the chromosomal lesion 
responsible for CML, t(9:22), did not induce the overall 
DNA methylation profile observed in the leukemia. 
Figure 4: Direct comparison of DNA methylation profiles for different leukemias.  DNA methylation profiles were compared for various leuke-
mias (CML, APL, Ph+ ALL, Ph- ALL, Ph- CD34+, and Ph+ CD34+ cells). Scatter plots were generated for direct comparisons of mean methylation 
beta values. (A) CML with APL (r=0.9475), (B) CML with Ph+ ALL (r=0.9416), (C) CML with Ph+ CD34+ cells (r=0.9343) (D) Ph+ ALL with Ph- ALL 
(r=0.9621), and (E) Ph+ CD34+ cells with Ph- CD34+ cells (r=0.9633), and (F) CML with Ph- ALL (r=0.9200).  
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Morphologic classification of leukemias into myeloid 
and lymphoid malignancies is the clinical standard, and 
the DNA methylation analysis we present supports this. 
The use of DNA methylation profiles to cluster leukemias 
is consistent with morphologic classification by stem cell 
of origin, such as myeloid versus lymphoid. DNA methyl-
ation profiles could distinguish between different types of 
leukemias, but CML was more closely related to APL than 
ALL or GIST. Thus, global DNA methylation profiles for 
CML did not resemble ALL even if they share Ph+, nor did 
CML and GIST share DNA methylation profiles even if both 
cancers are responsive to imatinib mesylate. It has been 
observed that cell lineage and tissue of origin determines 
promoter hypermethylation in cancers, but our study, to 
the best of our knowledge, is the first to show that cell of 
origin determines the DNA methylation pattern in leu-
kemia more than genetic defects [32,33]. 
Previous studies have shown that hematopoietic stem 
cells transfected with BCR-ABL phenotypically resemble 
CML cells [31]. However, we did not observe substantial 
changes in DNA methylation after transfection. Thus, it 
appears that DNA methylation profiles are largely based 
on the cell type of origin rather than the tumor develop-
ment process or chromosomal lesions involved.
There are some cancer-specific DNA methylation 
changes, as we found a minority of loci for which hyper and 
hypomethylation occurred with progression of CML. Inter-
estingly, when a CML patient was treated and responded 
to a DNA methyltransferase inhibitor, azacitidine, hyper-
methylated loci involved in CML progression displayed a 
decrease in methylation, while hypomethylated loci unex-
pectedly displayed an increase in DNA methylation levels. 
This suggests that changes in DNA methylation levels 
after treatment with DNA methyltransferase inhibitor may 
reflect a phenotypic change in response to therapy, rather 
than purely a direct effect on DNA methylation repres-
sion. However, the conclusion was based on one patient 
and these experiments need to be replicated in a greater 
number of individuals. 
Our data demonstrates that global DNA methylation 
profiles observed in CML and other cancers do not solely 
reflect the genetic events such as the translocation of the 
BCR-ABL gene. Instead our data suggest that DNA meth-
ylation profiles in cancer reflect the cancer cell of origin, 
such as myeloid versus lymphoid. Furthermore, treatment 
of CML patients with the DNA methyltransferase inhibi-
tor azacitidine led not only to decreases in DNA methyl-
ation at some loci, but also to an increase in methylation 
Figure 5: DNA methylation changes associated with CML progression. (A) DNA methylation levels at 84 loci showed a significant increase 
while 66 loci showed a significant decrease during progression of CML from chronic phase (bars) to accelerated phase (blue dots), and blast 
crisis phase (red dots). (B) Examination of 20 hypermethylated (left) and 20 hypomethylated (right) CML progression related loci with serial 
samples from a single patient.
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at another subset of hypomethylated loci. This suggests 
that the DNA methylation changes observed after azaciti-
dine treatment may not solely reflect direct inhibition of 
DNA methyltransferase, but also changes originating from 
other therapeutic effects. 
Our study is limited by primarily using peripheral 
blood instead of bone marrow stem cell samples from 
some of the patients, and by the limited clinical data 
available to us. The use of bone marrow specimens may 
be preferable over peripheral blood specimens, however, 
the relative ease of collecting peripheral blood over bone 
marrow enabled the collection and assessment of serial 
samples. In addition, cancer type was the predominant 
factor in determining methylation pattern, and not spec-
imen type, as we observed the clustering by cancer type 
and not by tissue (Figure 1 and 2). Detailed clinical infor-
mation on each subject may have also been useful, but we 
were limited due to the retrospective nature of the analy-
sis we performed and the requirement of staying within 
the institutional guidelines. Additionally, advances in 
technology would have enabled a far greater number of 
loci to be interrogated at once, as with Illumina’s Infin-
ium 27k and 450k microarrays. At the time of the analy-
sis, we used the latest technology available for assessing 
global DNA methylation, but technology has progressed 
sufficiently to enable an increase of two orders of magni-
tude in the number of loci that can be analyzed in such a 
manner. Although we concede that more detailed studies 
might reveal additional information, we expect the major 
insights from our study will not change. The Illumina 
GoldenGate platform provides sufficient genome wide 
coverage to demonstrate that the genetic events of leu-
kemogenesis do not induce the DNA methylation profiles 
observed. In addition, the observed DNA methylation 
Figure 6: Clinical response and DNA methylation changes induced by azacitidine (Vidaza®) treatment in a patient with CML. A) WBC count, B) 
DNA methylation of the LINE-1 repetitive element, and the mean DNA methylation of 1,007 CpG sites for Illumina GoldenGate analysis, and 
C) CML progression hyper- and hypomethylated loci following a course of azacitidine treatment.
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profiles reflected the tissue of origin and not the genetic 
events, such as BCR-ABL.
In summary, the chromosomal lesion responsible for 
CML, t(9:22), did not induce the overall DNA methylation 
profile observed in leukemia. Our results may contribute 
to understanding the epigenetic patterns in CML in rela-
tionship to the genomic translocation, and the therapeu-
tic effects of DNA methyltransferase in treating CML.
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